Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds.

Authors :: Schell WA
Jones AM
Garvey EP
Hoekstra WJ
Schotzinger RJ
Alexander BD
Source :: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2017 Feb 23; Vol. 61 (3). Date of Electronic Publication: 2017 Feb 23 (Print Publication: 2017).
Publication Year :: 2017
Abstract: The in vitro activities of fungal CYP51 inhibitors VT-1161 and VT-1129 were determined for Candida glabrata ( n = 34) and C. krusei ( n = 50). C. glabrata isolates were screened for FKS gene mutations. All isolates were resistant clinically and/or in vitro to at least one standard antifungal compound. VT-1161 and VT-1129 MICs for all isolates were at least 5-fold below achievable human plasma levels for VT-1161. VT-1161 and VT-1129 are promising for the treatment of resistant C. glabrata and C. krusei infections.<br /> (Copyright © 2017 American Society for Microbiology.)

Full Text Access

Tools